home / stock / atai / atai news


ATAI News and Press, ATAI Life Sciences N.V. From 10/17/23

Stock Information

Company Name: ATAI Life Sciences N.V.
Stock Symbol: ATAI
Market: NASDAQ
Website: atai.life

Menu

ATAI ATAI Quote ATAI Short ATAI News ATAI Articles ATAI Message Board
Get ATAI Alerts

News, Short Squeeze, Breakout and More Instantly...

ATAI - KKR acquires minority stake in biotech focused investment firm Catalio Capital Management

2023-10-17 09:05:31 ET More on KKR & Co. KKR: Looking Ahead To Higher Activity, Better Earnings In 2024 KKR, Flerie to form new pharma services platform Frontier Biosolutions Circor falls on report France probing KKR's planned deal over defense concerns F...

ATAI - Study Suggests LSD Could Treat OCD

Scientists from the Paris Brain Institute have discovered that psychedelic drugs such as LSD and psilocybin (magic mushrooms) may be able to treat obsessive compulsive disorder (OCD). French researchers are now investigating whether LSD (lysergic acid diethylamide) may also be effective again...

ATAI - DG, GRPN and GFI are among pre market gainers

2023-10-13 08:12:01 ET EHang Holdings  ( EH ) +47% Successfully Obtains Type Certificate for EH216-S Passenger-Carrying UAV System Issued by Civil Aviation Administration of China. Comtech Telecommunications ( CMTL ) +15% . SEALSQ  ( LAES ) +13% ....

ATAI - ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT Canada NewsWire TORONTO , Oct. 10, 2023 /CNW/ - This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Re...

ATAI - Governor Signs Bill Allowing Doctors to Prescribe Federally Rescheduled Psychedelics

Last week, California Governor Gavin Newsom signed a resolution that would allow healthcare professionals in the state of California to prescribe MDMA, psilocybin and any other drugs classified under Schedule I to patients if and when the drugs were approved by the FDA for an exemption or recla...

ATAI - atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being ...

ATAI - More Psychiatrists View Use of Psychedelics in Treating Mental Disorders Positively

A recently published study has found that more than 80% of psychiatrists positively view the use of psychedelic substances in treating a range of mental-health conditions. For the study, researchers from different institutions including Case Western Reserve University, Harvard Medical School an...

ATAI - atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comparable to those achieved with IV administr...

ATAI - Psychedelic drugs market to break $7B in 2029 led by these 3 meds

2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...

ATAI - Enthea Announces Nationwide Availability of Ketamine Treatment to Employees

Massachusetts-based healthcare provider Enthea has revealed that it is now offering psychedelic-assisted therapy coverage in employee healthcare plans nationwide . The provider was in the news last year when soap company Dr. Bronners announced that it would be offering psychedelic-assisted the...

Previous 10 Next 10